search button
Open Access

Efficacy and safety of surufatinib in the treatment of advanced solid tumors: a systematic evaluation and meta‑analysis

  • Authors:
    • Tianying Cai
    • Yonglang Cheng
    • Yichao Du
    • Peng Tan
    • Tongxi Li
    • Yifan Chen
    • Lin Gao
    • Wenguang Fu

  • View Affiliations

  • Published online on: May 10, 2023     https://doi.org/10.3892/ol.2023.13859
  • Article Number: 273

  • Copyright: © Cai et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Previous retrospective studies have suggested that surufatinib is effective for treating advanced solid tumors; however, the efficacy and safety of this drug needs to be investigated further via high‑quality evidence or randomized controlled trials. In the present study, a meta‑analysis was carried out to evaluate the safety and effectiveness of surufatinib for patients with advanced solid tumors. Systematic, electronic literature searches were conducted using PubMed, EMBASE, Cochrane Library and ClinicalTrials.gov. The disease control rate (DCR) of surufatinib in solid tumors was 86% [effect size (ES), 0.86; 95% confidence interval (CI), 0.82‑0.90; I2=34%; P=0.208] and the objective response rate was 16% (ES, 0.16; 95% CI, 0.12‑0.21; I2=48%; P=0.103), while the progressive disease rate was only 9% (ES, 0.09; 95% CI, 0.05‑0.15; I2=68%, P=0.014). Surufatinib showed different degrees of adverse reactions during the treatment of solid tumors. Among these adverse events, the incidence of increased levels of aspartate aminotransferase (AST) and alanine aminotransferase (ALT) were 24% (ES, 0.24; 95% CI, 0.18‑0.30; I2=45.1%; P=0.141) and 33% (ES, 0.33; 95%CI, 0.28‑0.38; I2=63.9%; P=0.040), respectively. In the placebo‑controlled trial, the relative risks (RRs) of elevated AST and ALT were 1.04 (95% CI, 0.54‑2.02; I2=73.3%; P=0.053) and 0.84 (95% CI, 0.57‑1.23; I2=0%; P=0.886), respectively. Overall, surufatinib was characterized by a high DCR and a low disease progression rate, thus indicating that it could exert a good therapeutic effect on solid tumors. Additionally, surufatinib showed a lower RR for adverse effects compared with other treatment modalities.
View Figures
View References

Related Articles

Journal Cover

June-2023
Volume 25 Issue 6

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

  • Journal Metrics
  • Impact Factor: 2.9
  • Ranked Oncology
    (total number of cites)
  • CiteScore: 6.3
  • CiteScore Rank: Q2: #119/366 Oncology
  • Source Normalized Impact per Paper (SNIP): 0.725
  • SCImago Journal Rank (SJR): 0.639
International Symposium on Molecular Medicine Conference Banner
The Cancer Story
World Congress on Advances in Oncology and International Symposium on Molecular Medicine Conference Banner
World Academy Of Sciences Banner
Heyday Road Banner

0

Copy and paste a formatted citation
x
Spandidos Publications style
Cai T, Cheng Y, Du Y, Tan P, Li T, Chen Y, Gao L and Fu W: Efficacy and safety of surufatinib in the treatment of advanced solid tumors: a systematic evaluation and meta‑analysis. Oncol Lett 25: 273, 2023
APA
Cai, T., Cheng, Y., Du, Y., Tan, P., Li, T., Chen, Y. ... Fu, W. (2023). Efficacy and safety of surufatinib in the treatment of advanced solid tumors: a systematic evaluation and meta‑analysis. Oncology Letters, 25, 273. https://doi.org/10.3892/ol.2023.13859
MLA
Cai, T., Cheng, Y., Du, Y., Tan, P., Li, T., Chen, Y., Gao, L., Fu, W."Efficacy and safety of surufatinib in the treatment of advanced solid tumors: a systematic evaluation and meta‑analysis". Oncology Letters 25.6 (2023): 273.
Chicago
Cai, T., Cheng, Y., Du, Y., Tan, P., Li, T., Chen, Y., Gao, L., Fu, W."Efficacy and safety of surufatinib in the treatment of advanced solid tumors: a systematic evaluation and meta‑analysis". Oncology Letters 25, no. 6 (2023): 273. https://doi.org/10.3892/ol.2023.13859